Statement of Changes in Beneficial Ownership (4)
January 03 2020 - 5:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Gionco David |
2. Issuer Name and Ticker or Trading Symbol
STEMLINE THERAPEUTICS INC
[
STML
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Accounting Officer |
(Last)
(First)
(Middle)
C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, ELEVENTH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/23/2019 |
(Street)
NEW YORK, NY 10022
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/23/2019 | | S | | 421 (1) | D | $10.58 (2) | 239517 (3) | D | |
Common Stock | 12/24/2019 | | S | | 2388 (1) | D | $10.97 (2) | 237129 (3) | D | |
Common Stock | 12/26/2019 | | S | | 1511 (1) | D | $10.75 (2) | 235618 (3) | D | |
Common Stock | 12/27/2019 | | S | | 197 (1) | D | $10.48 (2) | 235421 (3) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | In connection with the vesting of 9,505 shares on December 21, 2019, a total of 4,517 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 421 shares were sold on December 23, 2019; 2,388 shares were sold on December 24, 2019; 1,511 shares were sold on December 26, 2019; and 197 shares were sold on December 27, 2019. |
(2) | Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. |
(3) | Of the shares listed, 180,402 shares are restricted stock. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Gionco David C/O STEMLINE THERAPEUTICS, INC. 750 LEXINGTON AVENUE, ELEVENTH FLOOR NEW YORK, NY 10022 |
|
| Chief Accounting Officer |
|
Signatures
|
/s/ David Gionco | | 1/3/2020 |
**Signature of Reporting Person | Date |
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024